EGFR and non-small cell lung carcinoma: Another single-arm, open-label phase I trial (n=9) used a non-viral piggyBac transposon system to construct EGFR-targeted CAR-T cells for the treatment of patients with advanced NSCLC expressing high levels of EGFR (NCT03182816).